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Abstract
Inflammatory bowel disease (IBD), consisting of Crohn’s disease and ulcerative colitis (UC), results in substantial morbidity
and is difficult to treat. New strategies for adjunct therapies are needed. One candidate is the semi-essential amino acid, L-
arginine (L-Arg), a complementary medicine purported to be an enhancer of immunity and vitality in the lay media. Using
dextran sulfate sodium (DSS) as a murine colonic injury and repair model with similarities to human UC, we assessed the
effect of L-Arg, as DSS induced increases in colonic expression of the y
+ cationic amino acid transporter 2 (CAT2) and L-Arg
uptake. L-Arg supplementation improved the clinical parameters of survival, body weight loss, and colon weight, and
reduced colonic permeability and the number of myeloperoxidase-positive neutrophils in DSS colitis. Luminex-based multi-
analyte profiling demonstrated that there was a marked reduction in proinflammatory cytokine and chemokine expression
with L-Arg treatment. Genomic analysis by microarray demonstrated that DSS-treated mice supplemented with L-Arg
clustered more closely with mice not exposed to DSS than to those receiving DSS alone, and revealed that multiple genes
that were upregulated or downregulated with DSS alone exhibited normalization of expression with L-Arg
supplementation. Additionally, L-Arg treatment of mice with DSS colitis resulted in increased ex vivo migration of colonic
epithelial cells, suggestive of increased capacity for wound repair. Because CAT2 induction was sustained during L-Arg
treatment and inducible nitric oxide (NO) synthase (iNOS) requires uptake of L-Arg for generation of NO, we tested the
effect of L-Arg in iNOS
2/2 mice and found that its benefits in DSS colitis were eliminated. These preclinical studies indicate
that L-Arg supplementation could be a potential therapy for IBD, and that one mechanism of action may be functional
enhancement of iNOS activity.
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Introduction
Inflammatory bowel disease (IBD) is postulated to arise from the
interplay between luminal bacteria and the colonic mucosa [1,2].
There are two major forms: ulcerative colitis (UC) and Crohn’s
disease and approximately 1.4 million Americans are affected
[1,2]. The mechanisms underlying the abnormal immune system
response continue to be investigated with the hope that new
therapeutics may arise from a better understanding of pathophys-
iology. There is growing interest by patients with diseases such as
IBD in dietary supplements including macronutrient. One such
supplement that has been extensively promoted in the lay media
for enhancement of immunity and for use in a variety of health
concerns is L-arginine (L-Arg), and it is therefore used orally as a
complementary/alternative medicine. L-Arg is a semi-essential
amino acid that is important in protein synthesis. Because L-Arg
can be synthesized by the body, dietary intake of arginine is not
essential to maintain nitrogen balance in normal adults [3].
However, total body L-Arg may become depleted under stressful
conditions [4,5].
Cellular uptake of L-Arg is an active transport process mediated
primarily by cationic amino acid transporter (CAT) family
proteins, also known as y
+ transporters [6]. CAT proteins 1–4
have been described. CAT2 is the inducible transporter, and is
known to be upregulated in macrophages upon immune activation
[7,8], while CAT1 is constitutively expressed [8]. The potential
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proteins, in particular, are subject to competitive inhibition by L-
ornithine (L-Orn) and L-lysine (L-Lys) [9,10,11]. L-Arg is a
substrate for four enzymes, some of which exist as multiple
isoforms: arginase, nitric oxide (NO) synthase (NOS), arginine:
glycine amidinotransferase, and arginine decarboxylase [12].
Arginase enzymes are the endogenous antagonists to inducible
NOS (iNOS) because they compete for the same L-Arg substrate
by metabolizing it to L-Orn and urea [13], whereas iNOS
metabolizes L-Arg to NO and L-citrulline (L-Cit). There are two
isoforms of arginase: arginase I (Arg1) is abundant in liver and is
important for the urea cycle, and arginase II (Arg2) is abundant in
kidney and localizes to mitochondria [14,15]. L-Orn is used by
ornithine decarboxylase (ODC) to produce the polyamine
putrescine, which is then converted into the polyamines spermi-
dine and spermine by constitutively expressed spermidine and
spermine synthases, respectively. Notably, polyamines have been
associated with mucosal protection in the gastrointestinal tract
[16,17] including intestinal epithelial cell migration [18]. L-Orn
can also be acted upon by ornithine aminotransferase (OAT) to
produce L-proline (L-Pro) [19,20]. L-Pro is an important
precursor in collagen synthesis and has been demonstrated to be
involved in wound healing and cell migration in fibroblasts [21],
and in bovine retinal pigment epithelial cells [22].
There is literature suggesting that L-Arg metabolism in the
alimentary tract is altered in animal models of ischemic colitis and
inflammatory bowel disease [23]. In a rat model, L-Arg
supplementation attenuated the degree of tissue damage in
intestinal ischemia and promoted healing of intestinal mucosa
[24]. We have previously shown that in the Citrobacter rodentium
infection model of murine colitis there is a significant decrease in
the serum L-Arg concentration versus control mice, and that L-
Arg supplementation is clinically beneficial while inhibition of
polyamine synthesis is deleterious [25]. We have also reported
increased serum concentrations of L-Arg in patients with severe
UC, but relative arginine availability [26] was not increased in
these subjects due to the concomitant increase in serum L-Orn
and L-Lys [27], the competitive inhibitors for L-Arg transport
[10,11,27].
Although the precise mechanisms underlying the inflammation
and immune responses in IBD are still being investigated, various
inflammatory mediators, including proinflammatory cytokines
have been implicated in the disease process [28]. In particular,
increased secretion of proinflammatory cytokines is thought to be
important for exacerbation of IBD. A number of therapeutic
approaches targeting these factors are available. Administration of
an anti-TNF-a antibody in mice [29,30] and in humans
(Infliximab) has demonstrated efficacy [31,32,33], but these
treatments are often complicated by significant adverse effects
and expense. Additionally, anti-TNF-a therapies have limited
effectiveness with a therapeutic response in only about half of
patients [34], indicating the need to target more than just TNF
signaling.
Therefore, ongoing research into new treatment approaches,
including micronutrient supplements, may be useful. For example,
in our previous study in C. rodentium colitis in mice, L-Arg
supplementation led to decreased proinflammatory cytokine mRNA
levels [25]. This led toour goalofassessing the role of L-Arginmore
depth in the regulation of injury and inflammation in a model of
experimental colitis that has dysfunction of epithelial integrity and
immune dysregulation. Dextran sulfate sodium (DSS) is a heparin-
like polysaccharide that has been successfully used to induce colonic
mucosal injury in mice [35]. We selected this model for the current
study because DSS-induced colitis exhibits characteristics resem-
bling human UC, including weight loss, severe diarrhea, rectal
bleeding, loss of epithelium followed by ulceration and leukocyte
infiltration [35,36]. DSS has been linked to direct epithelial
cytotoxicity and interference with the normal interaction between
intestinal lymphocytes and epithelial cells [35,37,38].
We now report that in the DSS murine model of colonic injury,
oral L-Arg treatment improves clinical parameters as well as
proinflammatory cytokine and chemokine responses. Further-
more, we show a reduction in the tissue myeloperoxidase-positive
inflammatory cell infiltrate, improved mucosal integrity, and
enhanced epithelial cell migration. Genomic analysis by micro-
array revealed multiple differentially expressed genes after
exposure to DSS and many of these changes were abrogated with
L-Arg supplementation. Similarly, Luminex-based profiling re-
vealed that multiple proinflammatory cytokines and chemokines
upregulated by DSS were restored to normal levels with L-Arg
treatment. We also show that iNOS-deficient mice exhibited loss
of the salutary effects of L-Arg, implicating the iNOS/NO
pathway in the healing phase of DSS colonic injury.
Materials and Methods
Ethics statement
This study was carried out following recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol was approved by the
Institutional Animal Care and Use Committee of Vanderbilt
University (Protocol Number M/08/124). The study was also
approved by the Research and Development Committee of the
Veterans Affairs Tennessee Valley Healthcare System.
Animals
iNOS
2/2 C57BL/6 mice were originally obtained from The
Jackson Laboratory (Bar Harbor, ME) and bred in our facility.
Six-week-old wild-type (WT) C57BL/6 mice were purchased from
The Jackson Laboratory. Only male mice were used for
experiments, and all mice were used at 7 weeks of age. Animals
were maintained on a 12 h light/12 h dark cycle under biosafety
level 2 conditions. The mice had ad libitum access to a standard diet
and water until reaching the desired age for experiments.
Induction of DSS colitis
DSS (MW 36,000–50,000, MP Biomedical, Solon, OH) was
added to the drinking water of the mice [39] for 6 or 7 days, as
indicated in the Results. The final concentration was 4% (wt/vol).
Mice were allowed free access to water during the experiment. On
the day of sacrifice, the colons were removed, and after the length was
measured, they were rinsed clean, blotted dry, weighed and Swiss-
rolled for histology. In addition, two proximal and two distal 2 mm
2
s a m p l e sw e r er e s e r v e df r o me a c hc o l o n ,a n do n ef r o me a c hr e g i o n
was combined. Of these, one set of samples was placed in RNAlaterH
(Ambion, Austin, TX) for RNA analysis. The second set was snap-
frozen and used for protein analysis or amino acid profiling.
L-arginine
In all in vivo experiments, L-Arg (Sigma-Aldrich, St. Louis, MO,
catalogue number A8094) was administered as a 1% (wt/vol)
solution in the drinking water. L-Arg was used for 4 days after 6
days of DSS.
Survival and body weight measurement
To assess the effect of DSS treatment on the mice, survival and
changes in body weight of the animals were monitored daily over
the course of colitis development. Mice were monitored through-
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moribund, or lost more than 20% of initial body weight were
euthanized.
Assessment of histological score
Swiss-rolled colons were formalin-fixed and paraffin-embedded,
and 5 mm sections were stained with hematoxylin and eosin and
examined in a blinded manner by a gastrointestinal pathologist
(MKW). Tissues were scored on a 0–40 scale based on the
parameters of inflammation severity (0–3), inflammation extent
(0–3), and crypt damage (0–4) each multiplied by the percent
involvement (1=0–25%; 2=25–50%; 3=50–75%; and 4=75–
100%) as described previously [36,40,41].
mRNA analysis
mRNA was isolated as described [36]. Then, 1 mg of RNA was
reverse-transcribed using an iScript cDNA synthesis kit (Bio-Rad,
Hercules, CA). Each PCR reaction was performed with 2 mlo f
cDNA and 26 LightCyclerH 480 SYBR Green I Master Mix
(Roche, Indianapolis, IN). Primers for b-actin were used as
described [25,42]. Primers for CAT1 [43,44,45], CAT2
[43,44,45], Arg1 [14], Arg2 [14], iNOS [42], and ODC [45,46]
were used as previously described. The sequences for OAT
primers were as follows: (F) 59 ACCATTGCTGCTCTGCTGC-
GCCG 39, and (R) 59 TGAAGTACTGCCTGCCTTCCACA 39.
The thermal cycling conditions and the method used to calculate
relative expression have been described previously [44,45,46].
Western blot analysis
Samples of frozen colon tissue were suspended in CelLytic
TM
MT Mammalian Tissue Lysis/Extraction Reagent (Sigma)
containing EDTA-free Protease Inhibitor Cocktail Set III, and
Phosphatase Inhibitor Set I (EMD Chemicals) and disrupted by
three 10-second pulses of sonication at 40 W (Ultrasonic Processor
GE 130PB, Hielscher). For each mouse, 80 mg of protein was
resolved per lane on a 10% polyacrylamide gel (Bio-Rad) and
transferred overnight onto PVDF. After blocking with 5% milk for
2 h, CAT1, CAT2, iNOS, Arg1, Arg2, ODC, and b-actin were
detected by Western blotting as described [47]. CAT1 (67 kDa),
CAT2 (80 kDa), iNOS (130 kDa), Arg1 (38 kDa), Arg2 (40 kDa),
ODC (53 kDa), and b-actin (42 kDa) proteins were detected with
the following antibodies: rabbit polyclonal CAT1 and CAT2 Abs
(1/500; both from E. I. Closs, Johannes Gutenberg University,
Mainz, Germany); rabbit polyclonal iNOS Ab (1/2000; BD
Biosciences); rabbit polyclonal Arg1 Ab (1/200; Santa Cruz
Biotechnology, Santa Cruz, CA); goat polyclonal Arg2 Ab (1/200;
Santa Cruz Biotechnology, Santa Cruz, CA); goat polyclonal
ODC Ab (1/500; Santa Cruz Biotechnology, Santa Cruz, CA);
and mouse polyclonal b-actin Ab (1/10000; Sigma).
Assessment of serum and tissue amino acid
concentrations
Blood was collected at the time of sacrifice via cardiac puncture
and placed in an empty microcentrifuge tube. The samples were
placed on ice and were processed at 30 min. The samples were
centrifuged for 10 min at 13,4006g. The supernatant was
removed, aliquoted, snap frozen, and stored at 280uC until used
for amino acid analysis.
Frozen colonic tissue (20–30 mg) was lysed in 250 mL of a 10%
5-sulfosalicylic acid solution(SSA)(wt/vol)witha mortar and pestle-
type rotary homogenizer. The precipitated proteins were pelleted
via centrifugation at 13,4006g for 10 min and the supernatant
removed, snap frozen, and stored at 280uC for subsequent amino
acid analysis. Protein concentration was measured in the lysates by
the bicinchoninic acid (BCA) method as described [43].
Serum samples and tissue supernatants were provided to the
Vanderbilt Hormone Assay Core for amino acid analysis via high
performance liquid chromatography (HPLC). A dedicated Bio-
chrom (Holliston, MA) 30 Amino Acid Analyzer equipped with an
autosampler was used for the determination of amino acid
concentrations. Serum samples were deproteinized with an equal
volume of 10% SSA containing norleucine, which was added as an
internal standard. Tissue supernatants were diluted 1:1 with
loading buffer containing norleucine. Amino acid separation was
achieved utilizing a lithium citrate buffering system on an ion
exchange column, followed with a ninhydrin post column
derivatization at 1356C, and photometric detection. The peak
areas at 440 nm and 570 nm were integrated using EZChrom
software (Agilent Technologies, Santa Clara, CA).
The relative L-Arg availability was assessed in serum and
tissues. This was determined by the arginine availability index
(AAI) [27], calculated as [L-Arg]/([L-Lys]+[L-Orn]).
Tissue L-arginine uptake
The uptake studies were initiated by adding 10 mLo f[
14C]-L-Arg
(specific activity, 346 mCi/mmol) to the tissue for 5 min in
phosphate-buffered saline (PBS). The tissue was then washed 3 times
with cold PBS, and then lysed in 250 mL of radioimmunassay
precipitation assay (RIPA) buffer with a mortar and pestle-type rotary
homogenizer. The lysates were centrifuged for 20 min at 9,3006g
and supernatants were collected. Then, 10 mL of the supernatant was
added to 5 mL of scintillation fluid and the
14Cc o n t e n tw a s
determined in a scintillation counter. Protein concentration was
m e a s u r e di nt h el y s a t eu s i n gt h eB C Am e t h o d[ 4 3 ] .L - A r gt r a n s p o r t
values were expressed as pmol [
14C]-L-Arg/min/mg protein.
Assessment of colonic mucosal permeability
Two hours prior to sacrifice, mice were anesthetized with
inhaled, 5% isofluorane and given 200 mL of an 80 mg/mL
solution of fluorescein isothiocyanate (FITC)–dextran (Sigma
Aldrich, St. Louis, MO) via rectum using a 1 mL syringe with a
modified neonatal feeding tube. At the time of sacrifice, blood was
obtained via cardiac puncture, placed in an empty microfuge tube,
and placed on ice. The samples were centrifuged (9,3006g at 4uC)
for 20 min. Serum (50 mL)was mixed with an equal volume of PBS
and added to a black 96-well plate. The amount of fluorescence
was determined by spectrophotofluorometry with an excitation
wavelength of 482 nm and an emission wavelength of 528 nm
using serially diluted samples of the marker as a standard in a
BioTek (Winooski, VT) Synergy 4 plate reader.
Immunohistochemistry for myeloperoxidase
Formalin-fixed and paraffin-embedded 5 mm sections of Swiss-
rolled colons were stained with myeloperoxidase (MPO) prediluted
polyclonal antibody (Biocare Medical, Concord, CA) per the
manufacturer’s protocols. Subsequently, the slides were incubated
for 5 min at room temperature with 3,39-diaminobenzidine
(Biocare Medical, Concord, CA). The slides were examined in a
blinded manner by a gastrointestinal pathologist (MBP). Tissues
were scored as the number of MPO-positive cells per high-power
field (HPF). A total of 20 HPFs were assessed for each section. The
scores were then averaged for each section.
Assessment of tissue polyamine concentrations
Frozen colonic tissue (20–30 mg) was lysed in 500 mL RIPA
buffer with a mortar and pestle-type rotary homogenizer. Protein
L-Arg Supplementation Ameliorates DSS Colitis
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[43]. Polyamine levels in the tissue samples were determined by
precolumn dansylation reverse phase HPLC as reported previ-
ously [25,43,45].
Tissue cytokine and chemokine analysis
Colon tissues were reserved for protein analysis as described
above. The tissues were lysed in RIPA buffer with a mortar and
pestle-type rotary homogenizer, and used for Luminex assay as
described [48]. The lysates were then assessed by a BioPlexH (Bio-
Rad, Hercules, CA) multiplex bead-based antibody detection kit
according to the manufacturer’s protocols [49]. Protein concen-
tration was measured in the lysate using the BCA method as
described [43].
Microarray assessment
RNA samples were prepared from colon tissues as described
above. Each sample was quantified on the Nanodrop ND-1000
Spectrophotometer (ThermoFisher Scientific, Willmington, DE)
according to the manufacturer’s protocols and as described in
Supplemental Methods (Methods S1). Sample integrity was
assessed (Methods S1) using an Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA) according to the manufacturer’s
protocols. All of our samples had an RNA Integrity Number (RIN)
of .9 (scale 0–10). The reactions, hybridization, and data
processing were performed in the Vanderbilt Genome Sciences
Resource using the Ambion Whole Transcript Reaction kit
following the manufacturer’s protocol. Three biologic replicates
were profiled for each treatment group. The microarray data were
normalized using the robust multichip average (RMA) method
[50,51]. Additional details about the microarray techniques are
provided in Methods S1.
Analysis of microarray results
Hierarchical clustering of global gene expression patterns was
performed. First, the 12 total samples were clustered using
complete linkage analysis by the expression values of the probes
to examine the inter- and intra-group relationships. This
information was used to visually display the relationships based
on all the probes present. Differentially expressed genes (DEGs)
were selected by both a p value,0.01 based on Significance
Analysis of Microarrays (SAM) [50,52], and fold change .2. An
ANOVA analysis was performed to identify the DEGs among the
control, L-Arg, DSS, and DSS+L-Arg groups. To identify groups
of genes induced or downregulated by DSS that were then altered
by L-Arg supplementation, hierarchical clustering using a Pearson
correlation as the similarity metric of the mean of each group was
performed. Based on the gene expression values, four clusters were
characterized from the hierarchical dendrogram. From this
clustering, we were able to identify 4 distinct gene expression
patterns. The functional features of the DEGs were evaluated
using Ingenuity Pathway Analysis. The microarray data follow
MIAME requirements and have been deposited in the NCBI
Gene Expression Omnibus (GEO) database and can be accessed
at the following link (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?token=btwzpmaqccysany&acc=GSE34874).
Confirmation of microarray results by PCR
Confirmation of the gene expression values was performed on
the same RNA samples that were used for the microarray analysis.
We chose 4 genes to test. mRNA was isolated as previously
described. Then, 1 mg of RNA was reverse-transcribed using an
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Each PCR
reaction was performed with 2 mL of cDNA and 26LightCyclerH
480 SYBR Green I Master Mix (Roche, Indianapolis, IN). Primers
for b-actin were used as described [25,42]. The sense and anti-
sense primer sequences were as follows: MMP-3 59-GAAGAA-
GATCGATGCTGCCA-39 and 59-AGATCCACTGAAGAAGTA-
GAG-39,M M P - 1 05 9-GCTGTTTTTGAAAAGGAGAAGAA-39
and 59-AGTATGTGTGTCACCGTCCT-39, MMP-13 59-GCG-
GTTCACTTTGAGAACAC-39 and 59-GCATGACTCTCACA-
ATGCGA-39, and IL-6 59-TCCACGATTTCCCAGAGAAC-39
and59-AGTTGCCTTCTTGGGACTGA-39.Thethermalcycling
conditionsand themethodusedtocalculaterelativeexpressionhave
been described previously [44,45,46].
Assessment of epithelial proliferation
Mice were given an intraperitoneal injection of 5-bromo-29-
deoxyuridine (BrdU; 150 mL of a 10 mg/mL solution) 90 min
prior to sacrifice. The colon was obtained for epithelial cell
isolation and staining for E-cadherin as an epithelial cell marker as
previously described [36]. The isolated epithelial cells were then
stained for BrdU using the APC BrdU Flow Kit (BD Biosciences,
San Jose, CA) per the manufacturer’s protocols. The percentage of
BrdU positive, E-cadherin positive cells was assessed by flow
cytometry.
Epithelial migration assay
Colonic epithelial cells were isolated as above. Migration of
freshly isolated mouse colonic epithelial cells was measured using a
migration kit from Chemicon International (Millipore, Billerica,
MA; QCM Chemotaxis 8 mm 96-well Cell Migration Assay),
according to the manufacturer’s instructions. Briefly, 2.5610
4 cells
were plated in 96-well migration chambers. L-Arg (1.6 mM) was
added to the medium in the feeder trays underlying the cell
chambers, as well as in the migration chambers. Plates were
incubated for 24 h at 37uCi naC O 2 incubator. Cells and medium
from the top side of the migration chambers were discarded and
the migration chamber plates were placed on top of new 96-well
feeder trays containing 150 mL of cell detachment solution, and
incubated for 30 min at 37uC. CyQuant GR Dye was diluted with
lysis buffer and added to each well of the feeder trays, and
incubated for 15 min at room temperature. 150 mL of the mixture
from the feeder trays was transferred to new black 96-well plates
and fluorescence was measured at 480 nm and 520 nm in a
BioTek Synergy 4 plate reader.
Statistical analysis
In addition to the microarray analysis, quantitative data are
shown as the mean 6 SE. Statistical analyses were performed with
Prism version 5.0c (GraphPad Software, San Diego, CA). When
comparisons between multiple groups were made, analysis of
variance with the Student-Newman-Keuls posthoc multiple
comparisons test was performed. When comparisons between
only 2 groups were made, Student’s t test was performed. The log-
rank (Mantel-Cox) test was used for the survival analysis.
Results
DSS-induced colitis alters serum amino acid levels and
increases tissue L-arginine uptake
After 7 days of exposure to 4% DSS in the drinking water, there
was evidence of histologic injury versus control animals.
Representative photomicrographs are shown (Figure 1A). There
was a significant, 5.161.9–fold increase in L-Arg uptake detected
in the DSS tissues ex vivo (Figure 1B). In the mice treated with DSS,
there was an increase in serum L-Arg, L-Lys, L-Orn, L-Pro, and
L-Arg Supplementation Ameliorates DSS Colitis
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However, there was not a significant increase in the AAI
(Figure 1E), which takes into account the interaction of L-Orn
and L-Lys with the L-Arg transporter CAT2. In parallel with the
increases in serum amino acids, there were significant increases in
tissue L-Arg, L-Lys, L-Orn, and L-Pro concentrations versus
control (p,0.05), and a modest increase in L-Cit that was not
significant (Figure 1D). There was no significant increase in the
tissue AAI (Figure 1F). Taken together these data suggest that
there are increases in multiple amino acids in acute DSS colitis,
but there is no increase in AAI in either serum or tissue, indicating
that L-Arg supplementation could be useful particularly because
tissue L-Arg uptake is enhanced.
DSS-induced colitis alters L-Arg metabolic pathway
mRNA and protein expression
Given the alteration in serum and tissue L-Arg concentrations
and the increased L-Arg uptake ability of the colitis tissues, we
assessed the gene expression of major contributors to the L-Arg
metabolic pathway. After 7 days of DSS treatment, there was a
significant increase in the mRNA expression of the inducible L-
Arg transporter, CAT2, with a significant decrease in CAT1
(Figure 2A and 2B). The mRNA levels of the L-Arg metabolic
enzymes iNOS, Arg1 and Arg2 were all significantly increased
(Figure 2C–E), while the level of the downstream enzyme, ODC,
was modestly, but not significantly increased (Figure 2F). OAT
mRNA expression was significantly decreased (Figure 2G).
When protein expression was assessed after 7 days of DSS in
colon tissues by Western blot analysis (Figure 3), we confirmed the
decrease in CAT1, and increases in CAT2, iNOS, and Arg2 when
compared to control mice. There was a more modest increase in
Arg1 and no change in ODC levels (Figure 3).
L-Arg supplementation improves clinical parameters in
DSS-induced colitis in WT C57BL/6 mice
Mice were administered 4% DSS in their drinking water for 6
days followed by 4 days of water alone or 1% L-Arg in the
drinking water. We followed this protocol of oral administration
based on previous protocols from our laboratory and others
[25,53] demonstrating marked effects on colon pathology when L-
Arg is added to the drinking water, and evidence that oral amino
acid delivery to humans results in rapid and efficient absorption in
the small intestine and thus availability for distribution systemically
through the circulation [54,55]. It should be noted that we could
not administer the L-Arg during the DSS treatment, as we found
that the combination led to precipitation in the drinking water,
rendering the combination unreliable. Mice began losing body
weight after 5 days of treatment with DSS and in the DSS only
group this weight loss reached 10.7661.01% (89.2461.01% of
starting body weight) by day 7, 16.1961.18% (83.8161.18% of
starting body weight) by day 8, 19.3161.42% (80.6961.42% of
starting body weight) by day 9, and 19.9961.79% (80.0161.79%
of starting body weight) by day 10 (Figure 4A). In contrast, the
body weight loss of mice receiving supplemental L-Arg after
exposure to 6 days of DSS was only 7.1660.78% (92.8460.78%
of starting body weight) by day 7, 11.0561.09% (88.9561.09% of
starting body weight) by day 8, 11.4161.39% (88.5961.39% of
starting body weight) by day 9, and 10.7461.51% (89.2661.51%
of starting body weight) by day 10 (Figure 4A). The abrogation of
body weight loss by L-Arg supplementation was significantly
different at days 7 (p,0.01), and 8, 9, and 10 (p,0.001 for each)
versus the DSS only mice. Mice not given DSS that received L-
Arg alone did not exhibit any increase in their body weight, and in
fact they showed a modest decrease compared to the control group
receiving water alone (Figure 4A). Therefore, the increase in body
weight with L-Arg supplementation of the DSS-treated mice is not
attributable to a nonspecific effect on weight gain.
There was also substantially less mortality with L-Arg
supplementation (Figure 4B), as survival improved from 41.3%
in the DSS group to 85.3% in the DSS+L-Arg group (p,0.001).
Colon weight as a percentage of total body weight, a gross
indicator of inflammation, was markedly increased in the DSS
only group (Figure 4C), and this increase was significantly
attenuated in the DSS+L-Arg group (p,0.001). In addition, the
colon weight/colon length ratio, another parameter that quantifies
DSS-induced injury, showed a similar increase in the DSS group
that was also attenuated in the DSS+L-Arg group (Figure S1).
L-Arg supplementation abrogates the increased colonic
mucosal permeability in response to DSS-induced colitis
Colonic mucosal integrity was assessed by a FITC-dextran
permeability assay. There was a significant increase in colonic
mucosal permeability after exposure of mice to DSS for 6 days
followed by 4 days of water (p,0.001), compared to control mice
not receiving DSS (Figure 4D). This increase was abrogated in the
mice given DSS followed by supplemental L-Arg.
L-Arg supplementation reduces the MPO-positive cellular
infiltrate in DSS-induced colitis
DSS colitis is characterized by infiltration of immune cells in the
mucosa and submucosa, epithelial ulceration, and crypt damage
[36,40,41]. As expected, there was a substantial increase in the
colon histologic injury score after treatment with DSS followed by
water alone; however, L-Arg supplementation did not lead to a
significant difference in the histologic injury score (13.961.3 for
DSS, and 14.761.2 for DSS+L-Arg, data not shown). We
therefore assessed the cellular inflammatory infiltrate present in
more detail. MPO staining allows for reliable and simple in situ
quantification of polymorphonuclear cells (PMNs). As shown in
Figure 4E and 4F, there was a significant increase in MPO-positive
cells in the colon tissue after exposure to DSS compared to control
mice (p,0.001). Importantly, with DSS followed by L-Arg
compared with DSS alone, there was a 39.565.5% inhibition in
MPO-positive PMNs/HPF (p,0.01; Figure 4E).
Serum L-Arg concentration is no longer increased in a
recovery model of DSS-induced injury, while tissue L-Arg
and L-Pro remain increased
After 6 days of exposure to 4% DSS in the drinking water
followed by 4 days of water there was a modest increase in L-Arg
in the serum, but this was not statistically significant, and the small
further increase in serum L-Arg with 1% L-Arg in the drinking
water was also not significant (Table 1). However, there was a
significant increase in serum L-Lys levels in the DSS group
(Table 1), which is relevant because L-Lys can function as an
endogenous inhibitor of iNOS, as it blocks NO generation via
inhibition of L-Arg uptake, as we have demonstrated in
macrophages [43] and in colonic epithelial cells (data not shown).
Importantly, L-Arg supplementation of mice significantly reduced
circulating L-Lys levels (Table 1). However, DSS also led to
modest increases in serum L-Orn that were not changed with L-
Arg treatment, and for this reason the overall AAI was not
increased (Table 1). There were no significant alterations in serum
L-Cit or L-Pro levels in the DSS or DSS+L-Arg groups.
When tissue amino acids were measured (Table 2), there was a
substantial, 2.760.8–fold increase in tissue L-Arg concentration
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33546Figure 1. DSS-induced colitis alters serum amino acid levels and increases tissue L-Arg uptake. 7-week-old C57BL/6 mice received 4%
DSS in the drinking water or water alone (Ctrl) for 7 days. At sacrifice on day 7, blood was obtained via cardiac puncture. Serum was obtained after
30 min, snap frozen, and the amino acid profile was subsequently assessed by HPLC. The colon was removed and fresh pieces of tissue were
obtained to assess the amino acid profile and L-Arg uptake, as described in the Methods. (A) Representative photomicrographs showing presence of
colitis after 7 days versus Ctrl. (B) L-Arg uptake in colonic tissue. (C) Serum amino acid levels. (D) Tissue amino acid levels. (E) Serum AAI. (F) Tissue AAI.
n=4–8 per group. *p,0.05, **p,0.01, ***p,0.001 vs. control.
doi:10.1371/journal.pone.0033546.g001
Figure 2. DSS-induced colitis alters mRNA expression of L-Arg metabolic pathway genes. 7-week-old C57BL/6 mice received 4% DSS in
the drinking water or water alone (Ctrl) for 7 days. At sacrifice on day 7, the colon was removed and tissues were obtained for RNA isolation and
assessment of gene expression by real-time PCR. (A–G) Tissue mRNA expression of L-Arg metabolic pathway genes: L-Arg transporters CAT1 (A) and
CAT2 (B), metabolic enzymes iNOS (C), Arg1 (D), and Arg2 (E), as well as the downstream enzymes ODC (F) and OAT (G). n=4–10 per group. *p,0.05,
***p,0.001 vs. control.
doi:10.1371/journal.pone.0033546.g002
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33546after exposure to DSS versus control tissues (p,0.01). There was
no enhancement of colon tissue L-Arg levels after oral supple-
mentation. There was a modest increase in tissue AAI with DSS
treatment, but this was not significant, most likely due to the
increase in L-Lys and L-Orn in some of the mice, even though
there was not an overall increase in L-Lys and L-Orn levels. One
potentially important finding was that L-Pro was increased in
tissues from DSS-treated mice at the 10-day timepoint in this
recovery model, as this amino acid has been linked to wound
repair due to its role in collagen synthesis [21]. However, L-Arg
did not enhance the L-Pro levels, suggesting that L-Arg has
additional effects.
Sustained induction of CAT2, iNOS, and Arg1, and
downregulation of ODC in the DSS injury and repair
recovery model
To further examine L-Arg utilization, we conducted mRNA
expression studies of relevant genes after 6 days of DSS followed
by recovery with water alone or 1% L-Arg for 4 days. At this
timepoint, there was no longer a decrease in levels of CAT1
(Figure 5A) that was observed after 7 days of continuous DSS in
Figure 2, and CAT2 expression was still significantly increased
with DSS alone and with DSS+L-Arg, where a modest further
increase was observed (Figure 5B). iNOS (Figure 5C) and Arg1
(Figure 5D) mRNA levels both continued to be upregulated with
DSS at the 10-day timepoint in the absence or presence of L-Arg,
whereas the small increase in Arg2 levels with DSS was not
significant compared to control mice (Figure 5E). The expression
of the downstream enzyme ODC was somewhat reduced with
DSS, and L-Arg supplementation returned this back to control
levels (Figure 5F). Finally, there was a small decrease in OAT
expression with DSS alone, but surprisingly, in mice receiving
DSS+L-Arg there was a significant reduction in OAT levels
(Figure 5G). Because polyamines have been implicated in wound
repair, and we previously found an increase in polyamines with L-
Arg treatment in the C. rodentium model [25], we measured
polyamine levels in colonic tissues. There was a significant increase
in spermidine levels with DSS treatment with small, not significant
increases in putrescine and spermine, with an overall significant
increase in total polyamines (Figure 5H). However, L-Arg
supplementation did not have any effects on the individual or
total polyamine levels, despite the clinical improvement in these
mice. Taken together with the amino acid data, these findings
suggest that the clinical improvement of the mice in response to L-
Arg is not likely due to enhanced generation of polyamines by
ODC or L-Pro by OAT, but rather by other aspects of L-Arg
metabolism.
Altered tissue chemokine and cytokine levels in DSS
return to baseline with L-Arg supplementation
To provide further insight into the immunologic effects of L-Arg
treatment that might underlie the clinical improvement in the
mice, we conducted analysis of cytokines and chemokines in colon
tissue lysates by Luminex assay (Figure 6), using a 23 analyte kit.
For IL-12p70, all levels were below the limit of detection. For the
remaining analytes, exposure to DSS resulted in a significant
increase in the proinflammatory cytokines IL-1a, IL-1b, IL-6, IL-
17, G-CSF, GM-CSF, and the proinflammatory chemokines
eotaxin-1, KC, MCP-1, MIP-1a, MIP-1b, and RANTES
(Figure 6). Importantly, each of these increases with DSS were
significantly decreased by L-Arg supplementation (Figure 6). IL-4
was also decreased in the DSS+L-Arg group when compared to
DSS alone, but the level of IL-4 was below the limit of detection in
control mice, making these data difficult to fully assess. IL-2 and
IL-12 p40 were significantly increased after exposure to DSS, but
were not significantly altered by L-Arg supplementation (data not
shown). Cytokines not altered by exposure to DSS in this assay
included IL-3, IL-5, IL-9, IL-10, IL-13, TNF-a, and INF-c (data
not shown).
Analysis by microarray reveals multiple differentially
expressed genes in DSS-induced colitis which are altered
with L-Arg supplementation
Having detected substantial differences in cytokines and
chemokines, despite a lack of difference in histology, we sought
to establish the degree of difference between our experimental
groups by a more comprehensive genetic approach, namely
comparative transcriptome analysis. Hierarchical clustering was
conducted for the same four mouse groups in the 10-day model
used in Figures 4 and 5. There were 3 mice in each group. When
we compared expression values in the 12 samples, the DSS group
was markedly distinct from the control or the control+L-Arg
groups. Importantly, the DSS+L-Arg group segregated closely
with the two control groups not receiving DSS, rather than with
the DSS group (Figure 7A). We then assessed the differentially
expressed genes (DEGs) in different combinations of two group
comparisons, examining those with a p value,0.01 and a fold
change of .1.5 or .2 (Figure 7B). We chose the more stringent
criteria with the fold change .2 to proceed with further analysis.
There were 342 DEGs with DSS versus control, but only 59 of
these genes were altered in DSS+L-Arg versus control (Figure S2).
Figure 3. DSS-induced colitis alters L-Arg metabolic pathway
protein levels. 7-week-old C57BL/6 mice received 4% DSS in the
drinking water or water alone (Ctrl) for 7 days. At sacrifice on day 7, the
colon was removed and tissues were obtained for protein isolation and
assessment by Western blotting. Each lane represents a different
mouse. There were two separate blots that were used, so the
appropriate b-actin housekeeping gene control is placed under the
blots for the proteins of interest that were performed on those same
membranes.
doi:10.1371/journal.pone.0033546.g003
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33546Figure 4. L-arginine improves clinical parameters, mucosal integrity, and PMN inflammatory cell infiltration in DSS-induced colitis.
7-week-old C57BL/6 mice received 4% DSS in the drinking water or water alone (Ctrl) for 6 days, followed by administration of 1% L-Arg in the
drinking water, or water alone for 4 days. (A) Body weights of the mice were measured daily and presented as a percentage of their initial body
weight. **p,0.01, ***p,0.001 vs. DSS. (B) Survival analysis, with mortality based on .20% body weight loss. **p,0.01 vs. Ctrl. 111p,0.001 vs. DSS.
(C) At sacrifice, colons were removed, cleaned, and weighed. The fresh colon weight was determined as a percentage of the total body weight.
***p,0.001 vs. control and 111p,0.001 vs. DSS. In A–C, n=4–11 for controls, n=27–32 for treatments. (D) Prior to sacrifice, mice were anesthetized
and given FITC-labeled dextran via rectum. Blood was obtained by cardiac puncture at 2 h. Fluorescence was measured in the serum at 482 nm and
528 nm. In (D), n=4–8 for controls, n=14–16 for treatments. **p,0.01 vs. control. (E) and (F) At sacrifice, colons were removed, cut open
longitudinally, cleaned, Swiss-rolled and formalin fixed for future staining with MPO antibody. (E) The number of MPO-positive PMNs per HPF were
counted. 20 HPFs per slide were assessed. (F) Representative photomicrographs of MPO staining after DSS treatment alone or DSS followed by L-Arg
supplementation. n=4 for controls, n=9–10 for treatments. **p,0.01, ***p,0.001 vs. control. 11p,0.01 vs. DSS.
doi:10.1371/journal.pone.0033546.g004
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demonstrate marked changes with DSS versus control (Figure 7C)
and in DSS+L-Arg versus DSS alone (Figure 7D).
We performed a more in-depth analysis to identify the pattern
of alteration in gene expression related to the treatments given to
the mice. With hierarchical clustering using a Pearson correlation,
we specifically identified 132 genes upregulated in response to
DSS that were downregulated to control levels after L-Arg
supplementation (Figure 8A). There were also 27 genes that were
downregulated with DSS that returned to control levels in the
DSS+L-Arg group (Figure 8B). The detailed expression pattern of
genes that were altered by DSS and then affected by L-Arg
supplementation is presented in a specific heatmap (Figure 8C). As
these relationships cannot be directly accessed in the GEO
database, Tables S1 and S2 with each gene, its fold change, and p
value for the two detailed expression patterns are included in the
supplemental information.
The pathways enriched with DEGs between DSS+L-Arg and
DSS alone included leukocyte extravasation; IL-17, IL-10, and
CXC chemokine signaling pathways; cell migration; and cell
proliferation (Figure 8D). Also related to our findings of clinical
improvement with L-Arg there was a restoration to control levels
of DEGs associated with amino acid metabolism, protein synthesis,
and energy production.
We then used real-time PCR to confirm results obtained from
the microarray. Four gene targets from Figure 8A were assessed in
the same RNA samples submitted for microarray analysis. The
same expression patterns were seen in MMP-3, MMP-10, MMP-
13, and IL-16 (Figure S3).
L-Arg supplementation alters migration, but not
proliferation in isolated colonic epithelial cells from DSS-
induced colitis
Having noted DEGs related to both cellular movement and
growth/proliferation, we performed specific analyses of these
events in epithelial cells from colitis tissues. Freshly isolated CECs
from mice in the 10-day model were assessed in a migration assay
(Figure 9A). This revealed a modest increase in cell migration after
exposure to DSS alone, which was not statistically significant
compared to control mice. However, there was a further increase
in cell migration with L-Arg supplementation after DSS treatment
that was significant compared to both the control (p,0.01) and
DSS only (p,0.05) groups (Figure 9A). We also assessed the
presence of epithelial cell proliferation by BrdU staining
(Figure 9B). There was no significant increase in BrdU
+/E-
cadherin
+ cells after exposure to DSS or to DSS followed by L-Arg
supplementation, when compared to control mice (Figure 9B).
Taken together, these data indicate that enhancement of cell
migration, rather than cell proliferation, may contribute to the
beneficial effects of L-Arg during the recovery phase of DSS colitis,
as cell migration is an important component of epithelial wound
repair.
Loss of the clinical benefits of L-Arg supplementation in
DSS colitis in mice with iNOS deletion
Because there was no demonstrable effect of L-Arg on ODC/
polyamines or OAT/L-Pro, we focused on the other pathway of
L-Arg utilization, namely iNOS. We compared WT and iNOS
2/2
micethat weretreatedwith4%DSSfor6 daysfollowedby4 daysof
water alone or 1% L-Arg. As shown previously in Figure 3, WT
mice began losing body weight after 5 days of treatment with DSS
and continued to lose weight during the recovery period after
discontinuation of DSS on day 6 (Figure 10A). The iNOS
2/2 mice
exposed to DSS exhibited the same pattern of body weight loss as
the WT mice out to the 10-day timepoint (Figure 10A). However,
the marked attenuation of body weight loss with L-Arg treatment in
the WT mice was completely lost in the iNOS
2/2 mice. While in
the WT group the abrogation of body weight loss by L-Arg
supplementation was significantly different at days 7, 8, 9, and 10
versus the mice receiving water alone after DSS, there was no effect
of L-Arg supplementation in the iNOS
2/2 mice, such that the mice
receiving L-Arg after DSS overlapped with those that did not
(Figure 10A). As shown in Figure 10B, there was a significant
survival benefit with L-Arg supplementation in the WT mice
(consistent with our previous results in Figure 3B), but there was no
significant enhancement of survival with L-Arg in iNOS
2/2 mice
compared to WT or iNOS
2/2 mice exposed to DSS alone.
Similarly, the reduction in colon weight with L-Arg treatment of
WT mice receiving DSS was also eliminated in the iNOS
2/2 mice
(Figure 10C). Taken together, these data indicate that the clinical
Table 1. Amino acids in the serum from DSS colitis in the
presence or absence of L-Arg.
Control Control+L-Arg DSS DSS+L-Arg
n=10 n=8 n=13 n=20
L-Arg 125.0621.3 119.1615.8 180.1626.1 206.2623.8
L-Lys 309.9619.6 283.2615.2 448.7626.2*** 382.1618.6*1
L-Orn 106.3620.6 168.3631.6 203.9641.2 256.3653.2
L-Cit 38.962.2 40.964.0 48.364.7 43.662.1
L-Pro 75.167.1 80.264.6 97.9612.7 94.3610.3
AAI 0.360.1 0.360.1 0.360.1 0.360.1
7-week-old C57BL/6 mice received 4% DSS in the drinking water or water alone
for 6 days followed by administration of 1% L-Arg in the drinking water, or
water alone for 4 days. At sacrifice on day 10, blood was obtained via cardiac






Table 2. Amino acids in the colonic tissue from DSS colitis in
the presence or absence of L-Arg.
Control Control+L-Arg DSS DSS+L-Arg
n=10 n=8 n=17 n=14
L-Arg 2.360.4 2.660.3 6.261.1** 5.461.3*
L-Lys 5.060.9 3.660.4 7.361.3 5.660.9
L-Orn 0.560.1 0.860.1 0.960.2 1.060.2
L-Cit 0.760.1 1.460.3 1.160.2 1.060.1
L-Pro 2.660.5 3.560.5 7.061.1** 5.360.9*
AAI 0.560.1 0.660.1 0.660.1 0.660.1
7-week-old C57BL/6 mice received 4% DSS in the drinking water or water alone
for 6 days followed by administration of 1% L-Arg in the drinking water, or
water alone for 4 days. At sacrifice on day 10, the colon was removed and a
fresh piece of tissue was snap frozen. Amino acids were measured in the tissue
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PLoS ONE | www.plosone.org 10 March 2012 | Volume 7 | Issue 3 | e33546amelioration of colitis with L-Arg does not occur in iNOS
2/2 mice,
thus implicating iNOS in the beneficial effects of L-Arg.
Discussion
The objective of this study was to determine whether L-Arg
supplementation could abrogate disease in a murine model of
epithelial injury and colitis and thus could have potential as a
therapy in human IBD. The DSS model we used has been
compared to human UC due to the epithelial destruction and
presence of ulcers confined to the mucosa [36]. Moreover, the
DSS model provides an opportunity to examine treatments during
the recovery phase after withdrawal of the injurious agent, as we
performed in the current study. We have now demonstrated that
L-Arg supplementation is associated with improvement in clinical
measures of colitis, including body weight loss and survival;
morphological parameters such as colon weight; inflammatory
markers, including proinflammatory cytokine and chemokine
production; and epithelial cell migration in response to injury.
We have previously reported that L-Arg supplementation is
beneficial in C. rodentium infection, but in that model serum L-Arg
levels were depleted, whereas in the current work we found that
Figure 5. Effect of DSS treatment and L-Arg supplementation on L-Arg metabolic pathways. Mice received 4% DSS 6 1% L-Arg in the
drinking water as in Figures 3–4. (A) At sacrifice on day 10, a piece of colon was obtained for RNA isolation or polyamine determination by HPLC. (A–
G) Tissue mRNA levels of the genes indicated, as assessed by real-time PCR. (H) Tissue polyamine levels were assessed by HPLC as described in the
Methods. n=4–15 per group. *p,0.05, **p,0.01, ***p,0.001 vs. control. 1p,0.05 vs. DSS.
doi:10.1371/journal.pone.0033546.g005
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PLoS ONE | www.plosone.org 12 March 2012 | Volume 7 | Issue 3 | e33546serum L-Arg levels were increased in acute DSS colitis after 7 days
of continuous exposure. Similarly, we detected that in human UC
patients with severe colitis there were increased serum L-Arg
concentrations compared to normal controls [27]. However,
relative arginine availability, as calculated by the AAI, was not
increased in these human subjects due to the concomitant increase
in L-Orn and L-Lys that can act as competitive inhibitors for L-
Arg transport by CAT1 or CAT2 at the cell membrane
[6,10,11,26]. These human serum findings are comparable to
what we observed in the current study in the acute DSS model at
the 7-day timepoint, and in the 10-day injury and repair model we
detected no increase in the serum AAI. Importantly, there was an
increase in tissue L-Arg in the 10-day model, but the tissue AAI
was not increased. Interestingly, while there was a beneficial effect
of L-Arg treatment, this did not further increase tissue L-Arg
levels, suggesting that the additional L-Arg was metabolized. To
our knowledge, tissue L-Arg levels have not previously been
directly quantified in colon tissues from either animals or humans.
We also demonstrate for the first time that the L-Arg transporter,
CAT2, is upregulated in DSS colitis tissues in both the acute 7-day
model and in the 10-day injury and repair model, while CAT1 is
decreased in the first model and not altered in the second. These
data indicate that CAT2 is important in colitis, which is supported
by our data showing an increase in L-Arg uptake and in tissue L-
Arg levels with DSS colitis. Another point raised by the increased
L-Arg uptake in colitis tissues is that this occurs despite the fact
that DSS induces epithelial injury. This increase may be due to
increased L-Arg transport in intact epithelium adjacent to areas of
ulceration, as epithelial destruction is only partial in our model
[36], and/or uptake by other cells, especially infiltrating
macrophages, which we have shown to exhibit increased uptake
of L-Arg during mucosal inflammation [43].
Another intriguing finding in our study was a lack of
improvement in histologic injury score with L-Arg treatment,
despite substantial amelioration of mortality, body weight loss, and
colon weight. When we tested the effect of L-Arg at a later time
point, namely 6 days of DSS followed by 7 days of L-Arg, there
was also improvement in clinical parameters without improvement
in histology scores (data not shown). Also, when we tested a higher
concentration of L-Arg (5% in the drinking water), the mice did
not tolerate this in the control group, and the experiment could
not be continued. Similarly, we also observed that in the C.
rodentium model there was significant improvement in clinical
parameters without a substantial effect on histologic score [25].
However, when we specifically analyzed the MPO staining as a
marker of PMN infiltration, we found that the marked increase
with DSS was significantly attenuated with L-Arg treatment. This
is meaningful because neutrophil accumulation has been shown to
have an important role in DSS-induced colitis, since the disease
can be attenuated when anti-neutrophil serum is administered
[56]. These findings suggest that conventional scoring of
inflammation by hematoxylin and eosin staining may lack
sensitivity to detect differences in specific inflammatory cell
infiltrates in this model. Consistent with our MPO data, L-Arg
attenuated the increased tissue levels of the PMN growth factors
G-CSF and GM-CSF, and several chemokines linked to PMN
chemoattraction, such as KC and MIP-1a, in colonic tissue from
DSS-treated mice. In particular, the chemokine data provides
support for L-Arg as an anti-inflammatory agent, since chemokine
expression is recognized as a key early step in the pathophysiology
of inflammatory responses to colonic pathogens and has been
directly linked to the pathophysiology of human IBD [40]. Our
findings that L-Arg also effectively reduced other proinflammatory
mediators, such as the innate immune cell products IL-1a, IL-1b,
and IL-6, as well as the prototype Th17 cytokine, IL-17, suggest
that it may be broadly beneficial in colitis. The effect on IL-17 is
particularly noteworthy, as the Th17 subset of lymphocytes is now
considered to play an important role in the immunopathogenesis
of IBD [57,58].
An interesting question is whether induction of DSS colitis
results in a systemic immune response. To this end, we have
conducted Luminex-based profiling of 14 analytes that included a
selection of Th1, Th2/Treg, Th17 cytokines, as well as
chemokines. We found that 10 of these were significantly increased
in colitis tissues in acute colitis (7-day model), namely IFN-c, TNF-
a, IL-1b, IL-6, IL-10, IL-17, MIP-1a, KC, MCP-1, and MIP-1b,
demonstrating a mixed picture of Th1/Th17 cytokines plus pro-
inflammatory chemokines; when assessed in serum, 6 of these were
also increased, specifically IFN-c, TNF-a, IL-1b, IL-6, KC and
MCP-1, suggesting a Th1 bias, and a systemic pro-inflammatory
effect (data not shown). Because of the systemic IFN-c response,
we conducted exploratory studies of this prototype Th1 cytokine in
splenocytes from mice exposed to DSS for 6 days plus 4 days of
recovery, using a standard ex vivo model of culture with anti-CD3
and anti-CD28 followed by activation with phorbol 12-myristate
13-acetate (PMA) and ionomycin. When assessed by flow
cytometry, there was a marked increase in intracellular IFN-c in
CD4
+ lymphocytes from mice receiving DSS that was decreased
by 48% in cells from mice receiving L-Arg during the recovery
period (data not shown). Taken together, these additional findings
indicate further studies of the systemic immune response could be
a fruitful area of investigation to enhance the development of
rational immunomodulatory therapeutic strategies.
Given the improvement of multiple clinical parameters after L-
Arg supplementation, we assessed the potential effect on epithelial
migration, proliferation, and mucosal integrity. Our ex vivo
assessment of freshly isolated CECs showed a modest increase in
epithelial migration after exposure to DSS, and a significant further
increase with L-Arg supplementation. These data are consistent
with unpublished data from our lab using an in vitro wound
restitution assay in a colonic epithelial cell line demonstrating that
L-Arg supplementation improves epithelial wound repair. Poly-
amines,which area product ofL-Argmetabolism,havebeen shown
toplaya roleinintestinalcellmigration[18,59].However,wefound
that while there was a significant increase in the level of spermidine
andthe totalpolyaminesinresponsetoDSSexposure,therewasnot
a significant effect of L-Arg supplementation. There was also a
decrease in OAT expression, and a modest decrease in L-Pro levels
with L-Arg treatment in DSS colitis, also suggesting that L-Arg was
not exerting its effects via L-Orn metabolism. We plan to investigate
these issues with testing of other amino acids as supplements in the
DSS model in our future studies.
Figure 6. Altered tissue chemokine/cytokine levels in DSS return to baseline with L-Arg supplementation. Mice received 4% DSS 6 1%
L-Arg in the drinking water as in Figures 3–5. (A–L) At sacrifice on day 10, the colons were harvested and samples from the proximal and distal end
were obtained and snap frozen. They were subsequently lysed in RIPA buffer. Tissue lysates were assessed by BioPlexH multiplex bead-based
antibody detection using Luminex technology. Protein concentrations in the lysates were determined using BCA assay for normalization. n=5 mice in
control group, n=7–8 mice in treatment groups. *p,0.05, **p,0.01, ***p,0.001 vs. control. 1p,0.05, 11p,0.01, 111p,0.001 vs. DSS.
doi:10.1371/journal.pone.0033546.g006
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PLoS ONE | www.plosone.org 13 March 2012 | Volume 7 | Issue 3 | e33546Figure 7. Tissue microarray assessment identifying multiple differentially expressed genes after exposure to DSS. Mice received
treatments as in Figures 3–6. There were four groups, namely control (Ctrl), receiving water alone; control+L-Arg, receiving water for 6 days and L-Arg
for 4 days; DSS, receiving DSS for 6 days and water for 4 days; and DSS+L-Arg, receiving DSS for 6 days and L-Arg for 4 days. At sacrifice, a piece of
colon was obtained and placed in RNAlaterH. Three samples from each of the four groups were submitted for microarray assessment. (A) Hierarchical
clustering of the samples based on .16,000 protein-coding genes. The 12 samples were clustered by the expression values of the probes to examine
the inter- and intra-groups relationship of the samples. Note that the DSS group was markedly distinct from the Ctrl or the Ctrl+L-Arg groups, and the
DSS+L-Arg group segregated closely with the control groups not receiving DSS, rather than with the DSS group. (B) Table of the number of
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PLoS ONE | www.plosone.org 14 March 2012 | Volume 7 | Issue 3 | e33546Importantly, there was a sustained increase in CAT2 and iNOS
mRNA levels in the 10-day model. Moreover, we detected a 7.6–
fold increase in iNOS expression with DSS versus control in our
microarray analysis (p,0.01) that was not decreased with L-Arg
(data not shown). There is evidence that supports both protective
and deleterious roles of iNOS in colonic inflammation including in
the DSS model [23,25,60,61]. In our current studies investigating
the role of iNOS in the L-Arg effect, we found that iNOS
2/2 mice
no longer exhibited the clinical benefits of L-Arg supplementation
in the DSS model. In our previous report, C. rodentium colitis was
improved by iNOS deletion and L-Arg treatment of iNOS
2/2
mice led to an additive benefit [25], suggesting that in that colonic
differentially expressed genes (DEGs) based on p value,0.01 and fold change (FC) of .1.5 or .2. (C) Heatmap of the DEGs between the Ctrl and DSS
groups. (D) Heatmap of the DEGs between the DSS and DSS+L-Arg groups. Green is increased expression and red is decreased expression.
doi:10.1371/journal.pone.0033546.g007
Figure 8. Multiple pathways altered after exposure to DSS return to baseline with L-Arg supplementation. Pathway analysis based on
DEGs. (A) 132 genes were found to be upregulated in response to DSS that were subsequently downregulated to control levels after L-Arg
supplementation. (B) 27 genes were downregulated in response to DSS and returned to control levels after L-Arg supplementation. (C) Heatmap of
the DEGs based on the expression pattern of increased expression after exposure to DSS and decreased expression following L-Arg supplementation.
(D) Table showing examples of biologic and signaling pathways, derived from Ingenuity Pathway Analysis, that were found to be affected by these
altered gene expression patterns.
doi:10.1371/journal.pone.0033546.g008
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PLoS ONE | www.plosone.org 15 March 2012 | Volume 7 | Issue 3 | e33546Figure 9. Epithelial cell migration but not proliferation is altered in DSS colitis ± L-Arg. Mice received 4% DSS 6 1% L-Arg in the drinking
water as in Figures 3–8. On the day of sacrifice, colons were removed, and epithelial cells were isolated as described in the Methods. (A) Migration
assay, performed on freshly isolated CECs, as described in the Methods. (B) On the day of sacrifice, mice were given an i.p. injection of BrdU, CECs
were isolated, and stained for BrdU and E-cadherin as described in the Methods. Double-positive cells were detected by flow cytometry. n=4–8 for
controls, n=6–8 for treatments. **p,0.01 vs. control. 1p,0.05 vs. DSS.
doi:10.1371/journal.pone.0033546.g009
Figure 10. Benefits of L-Arg supplementation in DSS-induced colitis are lost in iNOS
2/2 mice. 7-week-old WT or iNOS
2/2 C57BL/6 mice
received 4% DSS 6 1% L-Arg in the drinking water as in Figures 3–9. (A) Body weights of the mice were measured daily and are presented as a
percentage of their initial body weight. *p,0.05, **p,0.01, ***p,0.001 vs. WT DSS. (B) Survival analysis, as in Figure 3. **p,0.01 vs. WT Ctrl;
111p,0.001 vs. WT DSS; #p,0.05 vs. iNOS
2/2 Ctrl; &p,0.05 vs. WT DSS L-Arg. (C) At sacrifice on day 10, colon weight as a percentage of the total
body weight was determined as in Figure 3. ***p,0.001 vs. WT Ctrl; 111p,0.001 vs. WT DSS; #p,0.05, ##p,0.001 vs. iNOS
2/2 Ctrl; &p,0.05 vs.
WT DSS+L-Arg. In (A–C), n=7–8 for controls, n=12–22 for treatments.
doi:10.1371/journal.pone.0033546.g010
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PLoS ONE | www.plosone.org 16 March 2012 | Volume 7 | Issue 3 | e33546infection overproduction of NO can be deleterious, and utilization
of L-Arg by alternative pathways is beneficial. However, in the
present studies, utilization of L-Arg by the arginase to ODC/OAT
pathway is not implicated in the improved response to DSS injury.
Consistent with this conclusion, our unpublished data show that
mice with heterozygous deletion of ODC exhibit a reduction in
colitis induced by DSS when compared to control mice.
Our data raise the question as to how iNOS may mediate the
beneficial effects of L-Arg. In some experimental systems there
have been reports of NO enhancing epithelial wound repair
[18,62,63,64]. Additionally, L-Arg supplementation has been
shown to be beneficial in cardiac ischemia, and notably, this has
been attributed to possible scavenging of oxyradicals by NO [65].
There also could be inhibitory effects of iNOS on immune cell
responses. We have reported that mice infected with the gastric
pathogen Helicobacter pylori exhibit inverse relationship between
gastric macrophage iNOS levels and gastric inflammation [43].
We also showed that mice with deletion of CAT2, which express
decreased iNOS in gastric macrophages, exhibit increased gastric
inflammation in this model [48].
Our microarray data provide strong evidence that L-Arg
treatment restores aberrant expression of numerous genes that are
upregulated or downregulated with DSS colitis. The specific
implication of leukocyte extravasation may be related to the
inhibitory effect of iNOS on adhesion of leukocytes to endothelial
cells[66],and couldhave therapeuticrelevanceconsideringfindings
that intestinal microvascular endothelial cells from IBD patients
exhibit reduced iNOS expression and a hyperadhesive phenotype
[67]. The additional pathways implicated in the microarray studies
represent specific targets for additional future studies, especially
genes implicated in cell migration, including the matrix metallo-
proteinases, some of which we confirmed in Figure S3.
In summary, the present study provides in vivo evidence that L-
Arg can improve clinical and biochemical parameters in a murine
colitis model of injury and repair with similarities to human UC.
The substantial effects of L-Arg on inflammatory mediators and
on signaling pathways suggests the potential for broad applicability
in other models, such as chronic models of colitis and colitis-
associated carcinoma.
Supporting Information
Figure S1 L-Arg improves colon weight to length ratio in
DSS colitis. 7-week-old C57BL/6 mice received 4% DSS 6 1%
L-Arg in the drinking water as in Figure 3. The fresh colon weight
in relation to colon length is shown for the same mice in Figure 3C.
***p,0.001 vs. control and 111p,0.001 vs. DSS. n=4–11 for
controls, n=27–32 for treatments.
(TIF)
Figure S2 Venn diagram for the DEGs identified from
the DSS vs. Control, DSS+L-Arg vs. Control, and DSS+L-
Arg vs. DSS groups. The red, blue and green circles represent
the number of DEGs for the group comparisons indicated. The
colored numbers within the circles represent the number of DEGs
unique to that comparison. The black numbers in the intersecting
regions represent genes that exhibit shared differential expression
between the overlapping groups.
(TIF)
Figure S3 Confirmation of microarray gene expression
data. 7-week-old C57BL/6 mice received 4% DSS 6 1% L-Arg
in the drinking water as in Figures 3–9. At sacrifice on day 10, the
colon was removed and a fresh piece of tissue was obtained for
RNA isolation. Confirmation of the gene expression values by
real-time PCR was performed on the same RNA samples that
were used for the microarray analysis. (A–D) MMP-3, MMP-10,
MMP-13 and IL-6 followed the same gene expression pattern as in
the microarray. *p,0.05, **p,0.01, ***p,0.001 vs. control.
11p,0.01, 111p,0.001 vs. DSS.
(TIF)
Table S1 Expression values for genes following the
pattern of increased in DSS and normalized with L-Arg
treatment. Expression levels, fold changes, and p values are
shown.
(XLS)
Table S2 Expression values for genes following the
pattern of decreased in DSS and normalized with L-Arg
treatment. Expression levels, fold changes, and p values are
shown.
(XLS)
Methods S1 Detailed methods for assessment of RNA
quality and for transcriptome analysis by microarray.
(DOC)
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